静脉血栓栓塞症溶栓治疗药物的研究进展
Advances in the Study of Drugs for Thrombolytic Therapy of Venous Thromboembolism
DOI: 10.12677/jcpm.2024.34359, PDF,   
作者: 孔玉虎：济宁医学院临床医学院，山东 济宁；孙自强*：济宁医学院附属医院血管外科，山东 济宁
关键词: 溶栓药物；静脉血栓栓塞症；药物治疗；深静脉血栓；Thrombolytic Drugs； Venous Thromboembolism； Drug Therapy； Deep Vein Thrombosis
摘要: 由于生活方式的改变和人口老龄化，静脉血栓栓塞症(VTE)的发病率逐年上升。作为一种严重的血管疾病，静脉血栓栓塞症对健康构成了极大的威胁。溶栓疗法在治疗VTE方面起着至关重要的作用；它能有效地再通血管，减少血栓负荷，并改善患者预后。近年来，治疗VTE的溶栓药物研发取得了重大进展。本文结合临床实践和循证医学的研究结果，对这些溶栓药物进行了探讨，为VTE的临床应用和科学研究提供了参考。
Abstract: The incidence of venous thromboembolism (VTE) is increasing annually due to changing lifestyles and an aging population. As a serious vascular disease, VTE poses significant health risks. Thrombolytic therapy plays a crucial role in treating VTE; it effectively recanalizes blood vessels, reduces thrombus load, and improves patient prognosis. Recent years have seen significant advancements in the development of thrombolytic drugs for VTE. This paper combines findings from clinical practice and evidence-based medicine to discuss these thrombolytic drugs, providing valuable insights for both clinical applications and scientific research on VTE.
文章引用：孔玉虎, 孙自强. 静脉血栓栓塞症溶栓治疗药物的研究进展[J]. 临床个性化医学, 2024, 3(4): 2519-2524. https://doi.org/10.12677/jcpm.2024.34359

参考文献

[1] Khan, F., Tritschler, T., Kahn, S.R. and Rodger, M.A. (2021) Venous Thromboembolism. The Lancet, 398, 64-77. [Google Scholar] [CrossRef] [PubMed]
[2] Lutsey, P.L. and Zakai, N.A. (2022) Epidemiology and Prevention of Venous Thromboembolism. Nature Reviews Cardiology, 20, 248-262. [Google Scholar] [CrossRef] [PubMed]
[3] Agnelli, G., Anderson, F., Arcelus, J., Bergqvist, D., Brecht, J., Greer, I., et al. (2007) Venous Thromboembolism (VTE) in Europe. The Number of VTE Events and Associated Morbidity and Mortality. Thrombosis and Haemostasis, 98, 756-764. [Google Scholar] [CrossRef] [PubMed]
[4] Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., et al. (2018) Anticoagulation Therapy for Venous Thromboembolism in the Real World—From the COMMAND VTE Registry. Circulation Journal, 82, 1262-1270. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, F., Gu, J. and Li, H.L. (2023) Diagnosis and Treatment of Venous Thromboembolism and Clinical Application of Inferior Vena Cava Filter in China. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 11, 1149-1156.
[6] Lind, M.M., Johansson, M., Själander, A. and Johansson, L. (2022) Incidence and Risk Factors of Venous Thromboembolism in Men and Women. Thrombosis Research, 214, 82-86. [Google Scholar] [CrossRef] [PubMed]
[7] Kumano, O., Akatsuchi, K. and Amiral, J. (2021) Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants. Biomedicines, 9, Article No. 264. [Google Scholar] [CrossRef] [PubMed]
[8] Yamashita, Y., Morimoto, T. and Kimura, T. (2022) Venous Thromboembolism: Recent Advancement and Future Perspective. Journal of Cardiology, 79, 79-89. [Google Scholar] [CrossRef] [PubMed]
[9] Stevens, S.M., Woller, S.C., Kreuziger, L.B., Bounameaux, H., Doerschug, K., Geersing, G., et al. (2021) Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest, 160, e545-e608. [Google Scholar] [CrossRef] [PubMed]
[10] Duffett, L. (2022) Deep Venous Thrombosis. Annals of Internal Medicine, 175, ITC129-ITC144. [Google Scholar] [CrossRef] [PubMed]
[11] Girardi, L., Wang, T., Ageno, W. and Carrier, M. (2023) Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, 824-831. [Google Scholar] [CrossRef] [PubMed]
[12] Undas, A. (2021) Fibrinolysis in Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 47, 480-489. [Google Scholar] [CrossRef] [PubMed]
[13] Paul, J.D. and Cifu, A.S. (2020) Management of Acute Pulmonary Embolism. JAMA, 324, 597-598. [Google Scholar] [CrossRef] [PubMed]
[14] Stevens, S.M., Woller, S.C., Baumann Kreuziger, L., Doerschug, K., Geersing, G., Klok, F.A., et al. (2024) Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021. Chest, 166, 388-404. [Google Scholar] [CrossRef] [PubMed]
[15] Xie, C., Zheng, N., Li, M., Zhang, Z., Huang, D., Xiao, M., et al. (2024) Comparative Analysis of Therapeutic Efficacy and Adverse Reactions among Various Thrombolytic Agents. Toxics, 12, Article No. 458. [Google Scholar] [CrossRef] [PubMed]
[16] Zia, M.A. (2020) Streptokinase: An Efficient Enzyme in Cardiac Medicine. Protein & Peptide Letters, 27, 111-119. [Google Scholar] [CrossRef] [PubMed]
[17] Rengaswamy, D. and Abdul Rahim, P. (2022) Fibrinolytic Enzyme—An Overview. Current Pharmaceutical Biotechnology, 23, 1336-1345. [Google Scholar] [CrossRef] [PubMed]
[18] Weng, C., Wang, X., Huang, L., Lin, X. and Liu, Q. (2021) Low-Dose Urokinase Thrombolytic Therapy for Patients with Acute Intermediate-High-Risk Pulmonary Embolism: A Retrospective Cohort Study. PLOS ONE, 16, e0248603. [Google Scholar] [CrossRef] [PubMed]
[19] Dotter, C.T., Rösch, J. and Seaman, A.J. (1974) Selective Clot Lysis with Low-Dose Streptokinase. Radiology, 111, 31-37. [Google Scholar] [CrossRef] [PubMed]
[20] Khalid, K., Elina Ahmad, R., Y.H. Tong, A., Yee Lui, S. and Zainol Abidin, I.Z. (2021) Pathophysiology of Streptokinase-Induced Hypotension in Acute Myocardial Infarction: A Systematic Review of Clinical Evidence. Archives of Medical Science—Atherosclerotic Diseases, 6, e85-e94. [Google Scholar] [CrossRef] [PubMed]
[21] Caballero López, A., Herrera Cartaya, C., Chávez González, E., González Reinoso, D., Caballero Font, J.A., Sánchez Vera, N., et al. (2020) Pulmonary Thrombosis in COVID-19 Treated by Thrombolysis: A Small Case Series Using Streptokinase. Seminars in Thrombosis and Hemostasis, 47, 431-435. [Google Scholar] [CrossRef] [PubMed]
[22] Sugioka, K., Nishida, T., Kodama-Takahashi, A., Murakami, J., Fukuda, M., Matsuo, O., et al. (2023) Urokinase-Type Plasminogen Activator Promotes Corneal Epithelial Migration and Nerve Regeneration. Experimental Eye Research, 233, Article ID: 109559. [Google Scholar] [CrossRef] [PubMed]
[23] Gurewich, V. (2019) Fibrinolysis: A Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown. Cardiovascular Drugs and Therapy, 33, 749-753. [Google Scholar] [CrossRef] [PubMed]
[24] Li, H., Wang, Y., Ren, X., Wang, J., Wang, H. and Jin, Y. (2023) Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis. Pharmacology, 108, 111-126. [Google Scholar] [CrossRef] [PubMed]
[25] Sanchez, O., Charles-Nelson, A., Ageno, W., Barco, S., Binder, H., Chatellier, G., et al. (2021) Reduced-Dose Intravenous Thrombolysis for Acute Intermediate—High-Risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 Trial. Thrombosis and Haemostasis, 122, 857-866. [Google Scholar] [CrossRef] [PubMed]
[26] Ren, T., Mi, Y., Wei, J., Han, X., Zhang, X., Zhu, Q., et al. (2024) Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery. Molecules, 29, Article No. 2325. [Google Scholar] [CrossRef] [PubMed]
[27] Shen, M., Wang, Y., Hu, F., Lv, L., Chen, K. and Xing, G. (2021) Thrombolytic Agents: Nanocarriers in Targeted Release. Molecules, 26, Article No. 6776. [Google Scholar] [CrossRef] [PubMed]
[28] Nedaeinia, R., Faraji, H., Javanmard, S.H., Ferns, G.A., Ghayour-Mobarhan, M., Goli, M., et al. (2019) Bacterial Staphylokinase as a Promising Third-Generation Drug in the Treatment for Vascular Occlusion. Molecular Biology Reports, 47, 819-841. [Google Scholar] [CrossRef] [PubMed]
[29] Hao, C., Ding, W., Sun, Q., Li, X., Wang, W., Zhao, Z., et al. (2019) Thrombolysis with rhPro-UK 3 to 6 Hours after Embolic Stroke in Rat. Neurological Research, 41, 1034-1042. [Google Scholar] [CrossRef] [PubMed]
[30] Fan, G., Wu, X., Jiao, W., Zhang, H. and Guo, D. (2022) Safety and Efficacy of Intracoronary Recombinant Human Prourokinase Administration in Patients with Acute Myocardial Infarction and ST-Segment Elevation: A Meta-Analysis of Randomized Controlled Trials. Experimental and Therapeutic Medicine, 25, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[31] Li, S., Gu, H., Feng, B., Dong, Q., Fan, D., Xu, Y., et al. (2024) rhPro-UK in Acute Ischemic Stroke within 4.5 h of Stroke Onset Trial-2 (the PROST-2 Study): Rationale and Design of a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Controlled Phase 3 Non-Inferiority Trial. International Journal of Stroke, 19, 1182-1187. [Google Scholar] [CrossRef] [PubMed]
[32] Mai, H., Chen, T. and Chen, F. (2022) Intra-Arterial Alteplase vs Placebo after Successful Thrombectomy and Functional Outcomes in Patients with Large Vessel Occlusion Acute Ischemic Stroke. JAMA, 327, 2455-2456. [Google Scholar] [CrossRef] [PubMed]
[33] Nishanth, K.R., Math, R.S., Shankar, M., Ravindranath, K.S. and Manjunath, C.N. (2019) Thrombolysis with Reteplase in Acute Pulmonary Embolism. Indian Heart Journal, 71, 464-467. [Google Scholar] [CrossRef] [PubMed]
[34] Li, S., Pan, Y., Wang, Z., Liang, Z., Chen, H., Wang, D., et al. (2021) Safety and Efficacy of Tenecteplase versus Alteplase in Patients with Acute Ischaemic Stroke (TRACE): A Multicentre, Randomised, Open Label, Blinded-Endpoint (PROBE) Controlled Phase II Study. Stroke and Vascular Neurology, 7, 47-53. [Google Scholar] [CrossRef] [PubMed]
[35] Warach, S.J., Dula, A.N. and Milling, T.J. (2020) Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke, 51, 3440-3451. [Google Scholar] [CrossRef] [PubMed]